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Methods: This observational study was conducted over a week on a repre-
sentative sample of French general practitioners (GP). All consulting primary
care men/women ≥50/60 y, with at least one other CVR factor (smoking, high
blood pressure (HBP), type 2 diabetes, HDL-c<0.40 g/L), not treated for dys-
lipidemia were included in the study. GP filled-in an on line questionnaire that
enabled SCORE calculation.
Results: GPs (n=1147) included 9049 patients with the following charac-
teristics: mean age: 68 y; male: 57%; LDLc>1.3 g/L: 57%; smoking: 21%;
HBP: 44%; type 2 diabetes: 21% HDL-c<0.4 g/L: 16%. 
According to SCORE, HCVR prevalence reached 50% in total population
(male: 49%, female: 51%). 50% of HCVR men/women were older than
>72.4/78.8 y. HCVR patients were older by 7.7/6.8 y for male/female (p <0.01)
than non-HCVR patients. Other significantly more frequent characteristics in
high CVR population are: HDL≥0.6 g/L (38%), untreated or uncontrolled
HBP (53%) and left ventricular hypertrophy (8%). Obesity is less frequent
(15%) in high CVR population. Highest HCVR prevalence was observed in
the Mediterranean population (54%), and lowest (47%) in the Northeast pop-
ulation (p <0.01). Adjustment by age and gender reduces regional disparities
between regions (52% vs 48%).
Conclusions: Half consulting primary care patients aged ≥50/60 y for men/
women with at least 1 risk factor on top of age and no lipid-lowering treat-
ment are at HCVR according to SCORE risk equation. Assessing cardiovas-
cular risk with risk equations appears particularly useful in this group of
patients. Besides age, which has the strongest impact on risk estimation, other
RF may be screened to improve HCVR management.
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Purpose: Prior studies have recognised non-O blood type as a risk factor
for venous thromboembolism (VTE). Though, ABO blood type contribution to
VTE recurrence risk is poorly studied. We sought to determine the impact of
blood type on VTE recurrences.
Methods: Our prospective cohort included 120 subsequent patients pre-
senting a first episode of pulmonary embolism (PE). In all cases, PE were
diagnosed with a CT scan. All participants were followed for at least
12 months after anticoagulation therapy discontinuation.
Results: Over a mean follow-up period of 30 months, the rate of recur-
rence was 8.9% per patient and per year. PE was unprovoked in 63 patients
(52.5%). Mean duration of oral anticoagulation was 6 months. Compared to O
blood type, the unadjusted hazard ratio (HR) of VTE recurrence for non-O
blood type was 1.97 (95%CI, 0.91-4.26, p=0.07). B blood type exposed to a
higher risk of VTE recurrence than O blood type with a HR of 2.6 (95%CI,
1.12-6.06, p=0.03). A and AB blood types were not associated with an
increased risk of VTE recurrence when compared to O blood type.
Conclusion: Non O blood type are involved not only in the occurrence of
a first episode of VTE but tend to contribute to VTE recurrence. Patients with
B blood type develop more VTE recurrence than others. The ABO blood type
could be one of the characteristics to be studied for the determination of the
length of anticoagulant treatment after a first episode of VTE
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Purpose: Statins have demonstrated their efficacy in many situations to
prevent cardiovascular risk. In this work we investigated the link between
chronic use of statins, type of subsequent acute coronary syndrome (ACS),
namely ST-elevation myocardial infarction (STEMI) or unstable angina/non
ST-elevation myocardial infarction (UA/NSTEMI), early complications and
their impact on one-year mortality in real life conditions.
Methods: Our study was based on 2006 data from the French MONICA
population-based registry which collects all cases of ACS occurring in people
aged 35-74 in 3 French areas. The sample consisted of 1951 hospitalized inci-
dent ACS (72 were excluded because of missing data). Relationship between
chronic use of statins and type of ACS or early complications (resuscitated
cardiac arrests and shocks) were analyzed through logistic regression. Impact
on one-year mortality was evaluated through Cox models. Analyses were
adjusted for patients’ characteristics (living area, age, gender and previous car-
diovascular treatments).
Results: Before index event, the rate of statins treated patients was
18%. The percentage of UA/NSTEMI among all hospitalized ACS was
45%; 54.5% in patients with previous statins treatment and 42.9% in those
without (p<0.0001). The adjusted odds ratio (OR) for UA/NSTEMI was
1.29 (p=0.049) for subjects with versus those without statins. There was a
significant association between statins and early complications (adjusted
OR 0.58; p=0.030). Statins treatment prior to event was associated with a
significant decrease in one-year mortality with an adjusted HR equal to
0.62 (p=0.017).
Conclusions: In our registry, people already treated with statins before an
incident ACS had a lower rate of one-year mortality. This may result from a
lower probability to develop STEMI, or early complications. However it
remains difficult to assess from these observational data what is related to the
treatment and what is related to potential confounding bias.
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Objectives: Recent data suggested that coronary heart disease (CHD) is
associated with non-amnesic mild cognitive impairment. Our purpose was to
assess cognitive performances at rest, VO2max, cardiac output (CO), and
cerebral hemodynamic changes during maximal exercise in patients with
stable CHD.
Methods: 22 stable fit CHD patients (70,9±9,3 years), 10 healthy age-
matched (68,6±8,6 years), 10 middle aged controls and 10 young controls
(< 40y) were included. We assessed cognitive performance with a standard
battery of paper and pencil tests, maximal exercise test on ergocycle with gas
exchange analysis with non-invasive CO measurement and Near-Infrared
Spectroscopy (NIRS) oxygenation indices at the brain level.
Results: There was no intergroup difference in VO2max or maximal CO
between cardiac and healthy age-matched individuals. Some cognitive tests,
especially for executive functioning, were significantly better for the healthy
matched group (Trail Making Test-B; Inhibition/Flexibility Stroop Task and
Backward Digit Span, p<0.05). For NIRS signals, we observed an increase in
deoxyhemoglobin (HHb) for maximal intensities and the classical inverted U-
shape curve for oxyhemoglobin (O2Hb) and hemoglobin difference
(Hbdiff=O2Hb-HHb) in each group. Considering fitness, intra-CHD group
